TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34695449

Group type: EXPERIMENTAL
Intervention: Fish oil lipid emulsion (FOLE) 1 g/kg/d
Number of subjects: 262

Group type: COMPARATOR
Intervention: Soybean oil lipid emulsion (SOLE) ≤3 g/kg/d
Number of subjects: 262
Study: 34695525

Group type: EXPERIMENTAL
Intervention: Ticagrelor 60 mg twice daily
Number of subjects: 1844

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg twice daily
Number of subjects: 1844

Group type: COMPARATOR
Intervention: PEGASUS-only group
Number of subjects: 1844

Group type: COMPARATOR
Intervention: COMPASS-only group
Number of subjects: 1844

Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 1844
Study: 34695615

Group type: EXPERIMENTAL
Intervention: Same-day intraprostatic fiducial marker placement, perirectal hydrogel injection, and CT and MRI simulation
Number of subjects: 21
Study: 34696602

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34696666

Group type: EXPERIMENTAL
Intervention: EIBI/APERS-P-SE preschools
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34696785

Group type: EXPERIMENTAL
Intervention: internet-delivered cognitive behavioral therapy (iCBT) program combined with exercise therapy and education
Number of subjects: 0

Group type: COMPARATOR
Intervention: exercise therapy and education
Number of subjects: 0
Study: 34696816

Group type: EXPERIMENTAL
Intervention: Serious game training for iER skills
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group playing a game without psychoeducational content
Number of subjects: 0
Study: 34697109

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 200

Group type: COMPARATOR
Intervention: Nadroparin overlapped with warfarin
Number of subjects: 200
Study: 34697111

Group type: EXPERIMENTAL
Intervention: Combination therapy of peg-IFN alpha 180 µg per week for 48 weeks combined with oral TDF 300 mg daily
Number of subjects: 272

Group type: COMPARATOR
Intervention: TDF monotherapy 300 mg oral daily
Number of subjects: 272
Study: 34697123

Group type: EXPERIMENTAL
Intervention: COMPASS (digital cognitive-behavioural therapy programme) with six therapist contacts over 10 weeks
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard charity support (SCS)
Number of subjects: 200
Study: 34697125

Group type: EXPERIMENTAL
Intervention: Live image-guided lead placement
Number of subjects: 130

Group type: COMPARATOR
Intervention: Empirical lead placement
Number of subjects: 130
Study: 34697911

Group type: EXPERIMENTAL
Intervention: Dedicated program including 'ad hoc' transportation and fast-track access to care; 12-week sofosbuvir/velpatasvir regimen without Ribavirin.
Number of subjects: 1470

Group type: EXPERIMENTAL
Intervention: Screening and linkage to care improvements through a PWUD-tailored service.
Number of subjects: 1470
Study: 34699062

Group type: EXPERIMENTAL
Intervention: Aseptic technique
Number of subjects: 1339

Group type: EXPERIMENTAL
Intervention: Single-use (sterile) catheter
Number of subjects: 1339

Group type: EXPERIMENTAL
Intervention: Hydrophilic-coated catheters
Number of subjects: 1339
Study: 34699069

Group type: EXPERIMENTAL
Intervention: Ponatinib
Number of subjects: 260
Study: 34699288

Group type: EXPERIMENTAL
Intervention: Computed tomography (CT) imaging
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard CT imaging
Number of subjects: 0
Study: 34699302

Group type: EXPERIMENTAL
Intervention: Self-reported ICS and SABA use
Number of subjects: 100

Group type: COMPARATOR
Intervention: Objective ICS adherence and SABA use
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Self-reported ICS usage
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Electronic medication monitors (EMMs)
Number of subjects: 100
Study: 34699592

Group type: EXPERIMENTAL
Intervention: Lisocabtagene maraleucel (liso-cel) at 50 × 106 or 100 × 106 CAR+ T cells
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Lisocabtagene maraleucel (liso-cel)
Number of subjects: 25
Study: 34699735

Group type: EXPERIMENTAL
Intervention: Bean-rich diet (0.3 cups beans/day) for 8 weeks
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 54
Study: 34699945

Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM) interventions
Number of subjects: 2000
Study: 34700344

Group type: EXPERIMENTAL
Intervention: VEN 200 mg and IBR 420 mg
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: All arms (including various dosing combinations)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Higher dosing combinations (IBR 560 mg and VEN 400 mg)
Number of subjects: 35
Study: 34700343

Group type: EXPERIMENTAL
Intervention: Reduced intensity conditioning (RIC) double umbilical cord blood transplantation (DUCBT)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Chimerism patterns observed after DUCBT
Number of subjects: 58
Study: 34702062

Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy
Number of subjects: 215
Study: 34702064

Group type: EXPERIMENTAL
Intervention: Intensive treatment (target SBP, 130-140 mm Hg)
Number of subjects: 4511

Group type: COMPARATOR
Intervention: Guideline-recommended treatment (target SBP <180 mm Hg)
Number of subjects: 4511
Study: 34702087

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34702124

Group type: EXPERIMENTAL
Intervention: VARIVAX™ 0.5 mL (1 dose for ages 12 months-12 years; 2 doses 6 weeks apart for ages 13-17 years)
Number of subjects: 100
Study: 34702229

Group type: EXPERIMENTAL
Intervention: WelTel mobile health platform
Number of subjects: 51
Study: 34702317

Group type: EXPERIMENTAL
Intervention: Real stimulation (4x1 anodal HD-tDCS montage, 2 mA, 20 min) during VRT sessions
Number of subjects: 58

Group type: COMPARATOR
Intervention: Active sham stimulation (2 mA, 30 s) during VRT sessions
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Real stimulation
Number of subjects: 58

Group type: COMPARATOR
Intervention: Active sham stimulation
Number of subjects: 58
Study: 34702336

Group type: EXPERIMENTAL
Intervention: TAPER (Team Approach to Polypharmacy Evaluation and Reduction)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Control (wait list)
Number of subjects: 360
Study: 34702567

Group type: EXPERIMENTAL
Intervention: Vigil
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 34702716

Group type: EXPERIMENTAL
Intervention: DICA 1
Number of subjects: 2215

Group type: EXPERIMENTAL
Intervention: DICA 2
Number of subjects: 2215

Group type: EXPERIMENTAL
Intervention: DICA 3
Number of subjects: 2215

Group type: EXPERIMENTAL
Intervention: CODA A
Number of subjects: 2215

Group type: EXPERIMENTAL
Intervention: CODA B
Number of subjects: 2215

Group type: EXPERIMENTAL
Intervention: CODA C
Number of subjects: 2215

Group type: EXPERIMENTAL
Intervention: CODA score
Number of subjects: 2215
Study: 34702747

Group type: EXPERIMENTAL
Intervention: Random Forests (RF) model
Number of subjects: 15465

Group type: EXPERIMENTAL
Intervention: Gradient Boosting Machine
Number of subjects: 15465

Group type: EXPERIMENTAL
Intervention: Extreme Gradient Boosting
Number of subjects: 15465

Group type: COMPARATOR
Intervention: NIHSS
Number of subjects: 15465
Study: 34702811

Group type: EXPERIMENTAL
Intervention: sintilimab 200 mg intravenously every 3 weeks for up to 24 months
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: sintilimab
Number of subjects: 28
Study: 34702867

Group type: EXPERIMENTAL
Intervention: RT-LAMP assay (EasyCoV) in saliva
Number of subjects: 1718

Group type: EXPERIMENTAL
Intervention: Saliva RT-LAMP
Number of subjects: 1718

Group type: COMPARATOR
Intervention: Nasopharyngeal RT-PCR
Number of subjects: 1718

Group type: COMPARATOR
Intervention: Saliva RT-PCR
Number of subjects: 1718

Group type: COMPARATOR
Intervention: Nasopharyngeal antigen testing
Number of subjects: 1718
Study: 34702956

Group type: EXPERIMENTAL
Intervention: Sirtuin 6 (SIRT6) overexpression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Linoleic acid treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: KLF10/SIRT6 signaling activation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genetic or pharmacological manipulation in KLF10-depleted PDAC cells
Number of subjects: 0

Group type: COMPARATOR
Intervention: KLF10 deficiency
Number of subjects: 0
Study: 34703348

Group type: EXPERIMENTAL
Intervention: Antihemophilic factor (recombinant) (rAHF; ADVATE) prophylaxis
Number of subjects: 54
Study: 34703985

Group type: EXPERIMENTAL
Intervention: Detectable circulating cell-free DNA (cfDNA) in advanced melanoma patients
Number of subjects: 149
Study: 34704389

Group type: EXPERIMENTAL
Intervention: Imipenem/cilastatin/relebactam (IMI/REL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Piperacillin/tazobactam
Number of subjects: 0
Study: 34704959

Group type: EXPERIMENTAL
Intervention: 6-component BE-EHR module intervention + standard care
Number of subjects: 66

Group type: COMPARATOR
Intervention: Standard care only
Number of subjects: 66
Study: 34704958

Group type: EXPERIMENTAL
Intervention: Follow-up at 1, 3, and 12 months after study inclusion
Number of subjects: 1700

Group type: EXPERIMENTAL
Intervention: Follow-up at 3 and 12 months
Number of subjects: 1700

Group type: EXPERIMENTAL
Intervention: Follow-up at 1 year
Number of subjects: 1700

Group type: EXPERIMENTAL
Intervention: Follow-up during the first 3 months after inclusion
Number of subjects: 1700
Study: 34705736

Group type: EXPERIMENTAL
Intervention: Baseline distress measured by the Traumatic Injuries Distress Scale (TIDS)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Higher levels of baseline distress (TIDS score)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: TIDS score of 5
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: TIDS score of 13
Number of subjects: 116
Study: 34706161

Group type: EXPERIMENTAL
Intervention: Dorzagliatin
Number of subjects: 0
Study: 34706553

Group type: EXPERIMENTAL
Intervention: Endovascular intervention for intermittent claudication (IC)
Number of subjects: 3326

Group type: EXPERIMENTAL
Intervention: Endovascular intervention for critical limb ischemia (CLI)
Number of subjects: 3326
Study: 34706564

Group type: EXPERIMENTAL
Intervention: Thrombectomy
Number of subjects: 4029
Study: 34706691

Group type: EXPERIMENTAL
Intervention: Psychodynamic therapy (PDT)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT)
Number of subjects: 22
Study: 34706698

Group type: EXPERIMENTAL
Intervention: First 1000 Days Program
Number of subjects: 264
Study: 34706710

Group type: EXPERIMENTAL
Intervention: Mind-Body Skills Groups (MBSGs)
Number of subjects: 39
Study: 34706764

Group type: EXPERIMENTAL
Intervention: Argus II Retinal Prosthesis System
Number of subjects: 10
Study: 34706777

Group type: EXPERIMENTAL
Intervention: 6-month complex lifestyle intervention program including instructor-led high-intensive exercise and nutritionist- and psychologist-led counselling
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 6-month complex lifestyle intervention program
Number of subjects: 16
Study: 34706874

Group type: EXPERIMENTAL
Intervention: Baricitinib (any dose)
Number of subjects: 3770

Group type: EXPERIMENTAL
Intervention: Baricitinib (2 mg or 4 mg)
Number of subjects: 3770
Study: 34706885

Group type: EXPERIMENTAL
Intervention: HIC-H patients treated with ICI regimens (n=196)
Number of subjects: 3570

Group type: COMPARATOR
Intervention: HIC-C patients treated with ICI regimens (n=88)
Number of subjects: 3570

Group type: EXPERIMENTAL
Intervention: HIC-H patients treated with ICI monotherapy
Number of subjects: 3570

Group type: COMPARATOR
Intervention: HIC-C patients treated with ICI monotherapy
Number of subjects: 3570

Group type: EXPERIMENTAL
Intervention: HIC-H patients treated with ICI plus chemotherapy
Number of subjects: 3570

Group type: COMPARATOR
Intervention: HIC-C patients treated with ICI plus chemotherapy
Number of subjects: 3570
Study: 34706884

Group type: EXPERIMENTAL
Intervention: Cardioversion (both direct current and pharmacological)
Number of subjects: 52057

Group type: EXPERIMENTAL
Intervention: Direct current cardioversion
Number of subjects: 52057

Group type: EXPERIMENTAL
Intervention: Pharmacological cardioversion
Number of subjects: 52057

Group type: COMPARATOR
Intervention: No cardioversion
Number of subjects: 52057
Study: 34706963

Group type: EXPERIMENTAL
Intervention: Immediate single blastocyst transfer in mNC-FET
Number of subjects: 464

Group type: COMPARATOR
Intervention: Postponed single blastocyst transfer in mNC-FET
Number of subjects: 464
Study: 34706967

Group type: EXPERIMENTAL
Intervention: Belatacept conversion
Number of subjects: 446

Group type: COMPARATOR
Intervention: CNI continuation
Number of subjects: 446
Study: 34707360

Group type: EXPERIMENTAL
Intervention: Lubricant treatment
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Hypotensive treatment
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Laboratory evaluations and vital signs
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Visual acuity, corneal and conjunctival staining, and chemosis
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Adverse events (AE) incidence
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Lubricant and hypotensive investigational drugs
Number of subjects: 166
Study: 34707489

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34708091

Group type: EXPERIMENTAL
Intervention: Oxiris Membrane
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard treatment)
Number of subjects: 0
Study: 34708171

Group type: EXPERIMENTAL
Intervention: Normothermic machine perfusion (NMP) for 120 minutes at 37 degrees Celsius
Number of subjects: 80

Group type: COMPARATOR
Intervention: Hypothermic machine perfusion (HMP) alone
Number of subjects: 80
Study: 34708217

Group type: EXPERIMENTAL
Intervention: Knee extensor rate of force development (RFD) early (0-50 ms)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Knee extensor rate of force development (RFD) late (100-200 ms)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Maximal voluntary force (MVF) adjusted for body weight
Number of subjects: 13
Study: 34708297

Group type: EXPERIMENTAL
Intervention: SLC2A1 HaeIII and HpyCH4V SNPs
Number of subjects: 342
Study: 34708399

Group type: EXPERIMENTAL
Intervention: Cannabis-based medicine (CBM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tetrahydrocannabinol (THC, dronabinol)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lu AG06466 (formerly known as ABX-1431)
Number of subjects: 0
Study: 34709196

Group type: EXPERIMENTAL
Intervention: Telerehabilitation (intervention group, n=220 patients)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Usual care (control group, n=110 patients)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Telerehabilitation (intervention group)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Interprofessional collaboration and quality of interprofessional shared decision making (measured with clinicians)
Number of subjects: 330
Study: 34709529

Group type: EXPERIMENTAL
Intervention: Very hard physical activity
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Total time of moderate to very hard physical activity
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Total caloric intake
Number of subjects: 54
Study: 34709605

Group type: EXPERIMENTAL
Intervention: Ixekizumab
Number of subjects: 566

Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 566
Study: 34709814

Group type: EXPERIMENTAL
Intervention: BMS-986278
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34710334

Group type: EXPERIMENTAL
Intervention: Family-based program focused on youth academic success
Number of subjects: 0
Study: 34710362

Group type: EXPERIMENTAL
Intervention: 2% alcoholic chlorhexidine and non-coated suture
Number of subjects: 5788

Group type: EXPERIMENTAL
Intervention: 2% alcoholic chlorhexidine and triclosan-coated suture
Number of subjects: 5788

Group type: EXPERIMENTAL
Intervention: 10% aqueous povidone-iodine and non-coated suture
Number of subjects: 5788

Group type: EXPERIMENTAL
Intervention: 10% aqueous povidone-iodine and triclosan-coated suture
Number of subjects: 5788

Group type: COMPARATOR
Intervention: 2% alcoholic chlorhexidine
Number of subjects: 5788

Group type: COMPARATOR
Intervention: Triclosan-coated sutures
Number of subjects: 5788
Study: 34711141

Group type: EXPERIMENTAL
Intervention: Psychotherapy
Number of subjects: 0
Study: 34711167

Group type: EXPERIMENTAL
Intervention: Quantra® system (QPlus® Cartridge)
Number of subjects: 38

Group type: COMPARATOR
Intervention: ROTEM® sigma (ROTEM® sigma complete + hep Cartridge)
Number of subjects: 38
Study: 34711189

Group type: EXPERIMENTAL
Intervention: MALDI-TOF spectra analysis
Number of subjects: 0
Study: 34711210

Group type: EXPERIMENTAL
Intervention: Reporting of incidental findings (IFs) of severe structural abnormalities
Number of subjects: 8252

Group type: EXPERIMENTAL
Intervention: Disclosure of IFs to participants
Number of subjects: 8252

Group type: EXPERIMENTAL
Intervention: Knowledge of IFs
Number of subjects: 8252

Group type: EXPERIMENTAL
Intervention: Overall participant perception of the study
Number of subjects: 8252

Group type: EXPERIMENTAL
Intervention: Perception of the restricted approach to IF management
Number of subjects: 8252
Study: 34711274

Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Provider capability to prescribe low-value ADT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Provider opportunity to prescribe low-value ADT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Provider motivation regarding ADT use
Number of subjects: 0
Study: 34711394

Group type: EXPERIMENTAL
Intervention: Transcatheter edge-to-edge repair (TEER)
Number of subjects: 37475

Group type: EXPERIMENTAL
Intervention: Transcatheter mitral valve replacement (TMVR)
Number of subjects: 37475
Study: 34711430

Group type: EXPERIMENTAL
Intervention: Transcatheter edge-to-edge repair (TEER)
Number of subjects: 37475

Group type: EXPERIMENTAL
Intervention: Transcatheter mitral valve replacement (TMVR)
Number of subjects: 37475
Study: 34711577

Group type: EXPERIMENTAL
Intervention: QuantiFERON test positive patients receiving antituberculosis treatment (ATT) for 6 months
Number of subjects: 1075

Group type: EXPERIMENTAL
Intervention: QuantiFERON test value >2 IU/mL
Number of subjects: 1075

Group type: EXPERIMENTAL
Intervention: QuantiFERON test threshold of 4 IU/mL
Number of subjects: 1075
Study: 34711597

Group type: EXPERIMENTAL
Intervention: Lower SpO2 targets during mechanical ventilation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard SpO2 targets during mechanical ventilation
Number of subjects: 0
Study: 34711598

Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 10078

Group type: COMPARATOR
Intervention: No BCG vaccination (control group)
Number of subjects: 10078
Study: 34711639

Group type: EXPERIMENTAL
Intervention: PPGR prediction model
Number of subjects: 121

Group type: COMPARATOR
Intervention: Baseline model (standard of care)
Number of subjects: 121
Study: 34711663

Group type: EXPERIMENTAL
Intervention: Peptide vaccination targeting mutated Gsα
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Combination of peptide vaccination with immune checkpoint inhibition
Number of subjects: 25
Study: 34711661

Group type: EXPERIMENTAL
Intervention: PPCI during the pandemic (2020)
Number of subjects: 16674
Study: 34711938

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) for 24-96 hours during the first 0-7 days after birth
Number of subjects: 140

Group type: COMPARATOR
Intervention: Inhaled nitric oxide (iNO)
Number of subjects: 140
Study: 34712113

Group type: EXPERIMENTAL
Intervention: Mesenchymal stromal cells (MSCs) administered through the internal carotid arteries
Number of subjects: 7
Study: 34712117

Group type: EXPERIMENTAL
Intervention: Retinal oxygen metabolism assessment in RMS patients
Number of subjects: 16

Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 16
Study: 34712229

Group type: EXPERIMENTAL
Intervention: Low Dose Radiation Therapy (LDRT) with a single dose per fraction of 0.5Gy
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Low Dose Radiation Therapy (LDRT)
Number of subjects: 125
Study: 34712513

Group type: EXPERIMENTAL
Intervention: Neoadjuvant treatment with intravenous PD-1 inhibitor toripalimab (240 mg), carboplatin (AUC 5), and pemetrexed (500 mg/m2) for three cycles.
Number of subjects: 0
Study: 34712714

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 0
Study: 34712893

Group type: EXPERIMENTAL
Intervention: Human milk nutrient concentrations (micronutrients)
Number of subjects: 0
Study: 34712928

Group type: EXPERIMENTAL
Intervention: Direct-acting antivirals (DAAs) - sofosbuvir with an NS5A inhibitor (ledipasvir, daclatasvir or velpatasvir)±ribavirin
Number of subjects: 3477
Study: 34712959

Group type: EXPERIMENTAL
Intervention: Endocrine therapy (letrozole) combined with CDK inhibitor ribociclib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Endocrine therapy (letrozole) alone
Number of subjects: 0
Study: 34713017

Group type: EXPERIMENTAL
Intervention: Internet Cognitive Behavioral Therapy with additional face-to-face outpatient psychotherapy (ICBT+)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Internet Cognitive Behavioral Therapy without additional face-to-face outpatient psychotherapy (ICBT)
Number of subjects: 168
Study: 34713023

Group type: EXPERIMENTAL
Intervention: Digital technology-based lifestyle-integrated exercise intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34713030

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34713106

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34713152

Group type: EXPERIMENTAL
Intervention: Human Papillomavirus Vaccination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Social Media Intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34713183

Group type: EXPERIMENTAL
Intervention: Internet-based conversational engagement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 34713337

Group type: EXPERIMENTAL
Intervention: Type QM-C hysterectomy
Number of subjects: 181
Study: 34713396

Group type: EXPERIMENTAL
Intervention: Increased PBR5-25 (marker of glycocalyx integrity)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: PBR5-25
Number of subjects: 600
Study: 34713415

Group type: EXPERIMENTAL
Intervention: Tapinarof cream 1% QD for 29 days
Number of subjects: 21